Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-504 in advanced dedifferentiated liposarcoma
NCT00969917Phase 2Withdrawn
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Jan 2010
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of retaspimycin in dedifferentiated liposarcoma (DDL), sponsored by Infinity Pharmaceuticals, Inc.. Planned start Jan 2010; status: withdrawn.
02
Drugs
retaspimycin
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT00969917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00969917.